Últimas noticias sobre Society Pass (NASDAQ:SOPA) Bolsa

Society Pass

Society Pass Inc is building an ecosystem of platforms and technology-enabled companies that synergistically work together to transform how consumers and merchants interact with one another in Southeast Asia and South Asia. Through the acquisition of companies and partnerships with visionary entrepreneurs, the company meets the growing demand for better services in sectors such as lifestyle, beauty, travel, and food and beverage. The company currently operates in Six reportable operating segments: Online Grocery and Food and grocery deliveries, Digital marketing, Online ticketing and reservation, Telecommunications Reseller, e-commerce, and Merchant Point of Sale (merchant POS). The company generates the majority of its revenue from the Digital marketing segment.

Society Pass Inc

Wells Fargo analyst Stephen Baxter maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Overweight and lowers the price target from $285 to $230.

News

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Universal Health Servs, Lowers Price Target to $230

Agreement Expands EzFill's Operations to Four New States
Deal Expected to Close December 2
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- EzFill Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZFL#NASDAQ">EZFL</a>), a leading mobile fueling company, has signed a definitive agreement to acquire the fueling division of Yoshi, Inc. with the aim of expanding its U.S operations and presence.
Under the terms of the agreement, EzFill will acquire Yoshi Mobility's existing mobile fuel service assets and allows EzFill to begin operations in four new states: California, Tennessee, Texas, and Michigan. EzFill will integrate Yoshi's assets, operations and customers into its growing infrastructure. With this acquisition, EzFill plans to not only strengthen the company's footprint in its existing markets but also take advantage of EzFill's national customers and begin offering services to them in those markets. EzFill will immediately add diesel fueling to the services currently offered by Yoshi in those markets which the Company believes will immediately increase revenues in those areas. Additionally, EzFill hopes to initiate an aggressive national expansion plan, positioning itself as a leading player in the on-demand fueling sector.

EZFL

EzFill Signs Definitive Agreement For The Purchase Of Yoshi Mobility's Fuel Division, Agreement Expands Operations To Four New States; Deal Expected To Close December 2; No Financial Terms Disclosed

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), the heavyweight of Big Tech, has hit a grim milestone in technical analysis: <a href="https://www.benzinga.com/topic/death-cross">a Death Cross</a>. 
With its share price slipping below key moving averages, MSFT stock has moved into bearish territory, casting doubts on its near-term prospects. Is this just a blip for the software giant, or the prelude to deeper woes?
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM.png" alt="" class="wp-image-663339" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">MSFT Stock: Bearish Signals All Around</h2>
At $418.19, MSFT stock price trails its 20-day, 50-day and even the 200-day simple moving averages (SMAs). Technical indicators are sounding alarms:
<ul>
<li>The 20-day SMA at $418.73, the 50-day SMA at $421.65 and the 200-day SMA at $421.81 all point to a bearish signal.</li>
<li>The eight-day SMA at $417.37, continues to be driven by bullish sentiment over the short term, driven by buying pressure.</li>
<li>The Moving Average Convergence Divergence (MACD) stands at -1.11, another red flag.</li>
<li>The Relative Strength Index (RSI) at 49.09 suggests that Microsoft isn't oversold yet but is heading toward bearish momentum.</li>
</ul>
These technical markers paint a strongly bearish picture. Yet, buying pressure persists, indicating that investors still see potential for a turnaround—a glimmer of bullish hope amidst the gloom.
Read Also: <a href="https://www.benzinga.com/24/11/42160614/microsoft-ceo-satya-nadella-calls-for-culture-change-after-security-breaches-that-led-to-voluntary-pay-cut">Satya Nadella Promises &#8216;Culture Change&#8217; After Security Lapses Return To Haunt Microsoft 20 Years After Bill Gates Launched A Similar Initiative</a>
<h2 class="wp-block-heading">The ProPublica Bombshell</h2>
Compounding Microsoft's technical woes is a ProPublica investigation that has raised ethical and legal concerns over the company&#8217;s federal contracting practices. As detailed in the <a href="https://www.propublica.org/article/microsoft-white-house-offer-cybersecurity-biden-nadella">report</a>, Microsoft's "White House Offer"—a supposedly altruistic pledge to bolster government cybersecurity—was a calculated business maneuver. 
The plan involved providing free upgrades and consulting services to federal agencies, locking them into Microsoft's ecosystem. Once the "free" period ended, agencies had little choice but to continue with costly subscriptions and Azure services, effectively squeezing out competitors.
This strategy not only strengthened Microsoft's grip on federal business but also invited scrutiny for potentially violating federal procurement and antitrust laws. Legal experts argue that the deal sidesteps open competition, raising concerns about its long-term implications for government reliance on a single vendor.
<h2 class="wp-block-heading">A Double-Edged Sword</h2>
While the technical indicators signal bearishness, the buying pressure suggests a tug-of-war between short-term skepticism and long-term optimism. Microsoft's market dominance—bolstered by its lucrative cloud business and strategic maneuvers—remains a formidable moat. 
However, the ethical controversies surrounding its federal contracts could dent investor confidence and invite regulatory headwinds.
<h2 class="wp-block-heading">The Verdict</h2>
Microsoft's Death Cross is a wake-up call for investors. With the stock under technical pressure and the ProPublica revelations casting a shadow over its business practices, the path forward is murky. 
Bulls might see this as a chance to buy on weakness, banking on Microsoft's resilience. Bears, however, have a compelling case to remain cautious as the stock navigates this precarious juncture.
For now, Microsoft's crossroads is a reminder that even the mightiest of tech giants are not immune to scrutiny—or the market's harsh judgment.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/24/11/42136902/microsofts-brad-smith-urges-trump-government-to-tackle-growing-cyber-threats">Microsoft&#8217;s Brad Smith Urges Trump Government to Tackle Growing Cyber Threats</a></li>
</ul>
Image: Shutterstock

Long Ideas

Technicals

Signals

Tech

Trading Ideas

MSFT

Microsoft's Death Cross: Tech Giant Faces A Double Blow With FTC Pressure

SMTK

SmartKem Shares Halted On Circuit Breaker To The Downside, Stock Now Up 39.4%

<a href="https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales" title="https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales">https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales</a>

AAPL

"Apple's Thin iPhone Has No Physical SIMs—That Could Dampen China Sales" - The Information

JMP Securities analyst Jordan Bender maintains MGM Resorts Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) with a Market Outperform and lowers the price target from $54 to $50.

JMP Securities Maintains Market Outperform on MGM Resorts Intl, Lowers Price Target to $50

Macro Economic Events

Econ #s

Economics

Dallas Fed Manufacturing Business Index For November -2.7 Vs -2.4 Est.; -3.0 Prior

William Blair analyst Jeff Schmitt initiates coverage on Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform rating.

Initiation

NDAQ

William Blair Initiates Coverage On Nasdaq with Outperform Rating

In the current session, the stock is trading at $116.06, after a 0.36% increase. Over the past month, Walt Disney Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) stock increased by 21.08%, and in the past year, by 25.83%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732548611_0.png" alt="Past Year Chart" />

<h3>Walt Disney P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Walt Disney has a lower P/E than the aggregate P/E of 52.76 of the Entertainment industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732548611_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Walt Disney

U.S. stocks settled higher on Friday, with the Dow Jones index closed at a fresh record level during the session. Major indices on the Wall Street recorded gains last week, with the Dow gaining around 2% and the S&amp;P 500 adding around 1.7%.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Trevor Walsh
<ul>
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 89%</li>
<li>Latest Rating: Maintained a Market Outperform rating on Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) and raised the price target from $380 to $415 on Nov. 21. This analyst sees more than 8% increase in the stock.</li>
<li>Recent News: On Nov. 20, Palo Alto reported first-quarter revenue of $2.14 billion, beating the consensus estimate of $2.12 billion. The cybersecurity company reported quarterly earnings of $1.56 per share, beating analyst estimates of $1.48 per share, according to Benzinga Pro.</li>
</ul>
Analyst: Chris Kotowski
<ul>
<li>Analyst Firm: Oppenheimer</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Downgraded rating on JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) from Outperform to Perform on Nov. 20.</li>
<li>Recent News: On Nov. 7, J.P. Morgan Real Estate Income Trust, Inc. disclosed the acquisition of a two-site, three-building logistics and storage portfolio in Tampa and Pinellas Park, Florida, for $25.8 million, excluding closing costs.</li>
</ul>
Analyst: Andrew Kaplowitz
<ul>
<li>Analyst Firm: Citigroup</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) and cut the price target from $166 to $161 on Nov. 20. This analyst sees around 19% upside in the stock.</li>
<li>Recent News: On Nov. 19, the company reported fourth-quarter revenue growth of 4.4% year-over-year to $2.96 billion, beating the consensus of $2.368 billion.</li>
</ul>
Analyst: Zachary Fadem
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Equal-Weight rating on Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) and increased the price target from $140 to $165 on Nov. 21. This analyst sees around 4% decline in the stock.</li>
<li>Recent News: On Nov. 20, Williams-Sonoma reported better-than-expected third-quarter financial results.</li>
</ul>
Analyst: Aaron Rakers
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Overweight rating on NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and raised the price target from $165 to $185 on Nov. 21. This analyst sees more than 30% upside in the stock.</li>
<li>Recent News: In a recent interview, Nvidia CEO Jensen Huang shared his thoughts on the company&#8217;s focus on supply as demand remains &#8220;incredible,&#8221; a development that was a big topic in the company&#8217;s recent financial results.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Pre-Market Outlook

NVDA

PANW

This Analyst With 85% Accuracy Rate Sees Over 30% Upside In Nvidia - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

JMP Securities analyst Jordan Bender maintains Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) with a Market Outperform and raises the price target from $35 to $36.

GDEN

JMP Securities Maintains Market Outperform on Golden Entertainment, Raises Price Target to $36

UBS analyst Joseph Spak maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Sell and raises the price target from $197 to $226.

TSLA

UBS Maintains Sell on Tesla, Raises Price Target to $226

WIIM

EVTL

Vertical Aerospace shares are trading higher after the company announced it secured an agreement where Mudrick Capital will commit up to $50 million in the next equity round.

Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) is giving traders a rollercoaster they can't resist. The server maker, famous for its AI systems powering Nvidia Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips, saw its stock skyrocket 65% in a single week.
The stock opened the trading day of Monday, Nov. 18 at $20.03/share and closed Friday, Nov. 22 at $33.15/share. The stock was seen attempting to claw its way back from a six-month slump that wiped out nearly 60% of its value. 
But the road ahead is anything but smooth.
<h2 class="wp-block-heading">SMCI&#8217;s Nasdaq Drama: Staying In The Game</h2>
Super Micro recently faced a potential delisting scare after failing to meet Nasdaq's filing requirements. In response, the company hired a new independent auditor and vowed to file its earnings report soon. 
The stakes couldn't be higher; failure to follow through could wreak havoc on the stock, sending it into freefall once again. For now, though, traders appear to be betting on a redemption arc—just in time for the holidays.
Read Also: <a href="https://www.benzinga.com/tech/24/11/42008585/why-super-micros-survival-may-hinge-on-nvidia-earnings-nasdaq-deadline">Why Super Micro&#8217;s Future May Hinge On Nvidia Earnings, Nasdaq Deadline</a>
<h2 class="wp-block-heading">SMCI Stock&#8217;s Technical Tug-of-War</h2>
While last week's rally signals hope, SMCI's technical indicators paint a more nuanced picture. 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25095056/Screenshot-2024-11-25-at-8.17.52-PM.png" alt="" class="wp-image-663488" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25095056/Screenshot-2024-11-25-at-8.17.52-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25095056/Screenshot-2024-11-25-at-8.17.52-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
SMCI stock, trading at $37.03, sits above its eight-day ($26.51) and 20-day ($27.06) simple moving averages (SMAs) — clear bullish signals. However, the longer-term outlook isn't as rosy. With the 50-day SMA at $38.00 and the 200-day SMA at a lofty $69.70, both point to bearish signals, reflecting the steep declines earlier this year.
Adding to the mixed signals, the moving average convergence/divergence (MACD) indicator stands at -2.63, further suggesting caution, while the relative strength index (RSI) hovers at 57.97, indicating neither overbought nor oversold conditions. 
It's a battleground for bulls and bears, and the options market <a href="https://www.tradingview.com/news/tradingview:82d432982094b:0-smci-super-micro-jumps-65-in-a-week-as-traders-ramp-up-bets-on-roaring-comeback/">implies</a> double-digit percentage swings could persist for weeks.
<h2 class="wp-block-heading">SMCI Stock From Boom To Bust — &amp; Back?</h2>
Super Micro shares once surged to over $122/share by March, riding the AI wave. But since peaking, the stock has shed 69% of its value as it trades around $38/share &#8211; leaving investors wondering if the magic is gone for good. 
Even after the recent rally, the stock has only managed a modest 33.70% gain year-to-date.
<h3 class="wp-block-heading">The Comeback Question</h3>
With Nasdaq compliance hanging in the balance and volatility dominating its trading patterns, Super Micro has a lot to prove. Can the server manufacturer capitalize on its AI-driven partnerships and rebuild investor trust, or will it face another wipe out?
Traders are watching closely, and the clock is ticking.
For now, Super Micro is a high-stakes bet. The potential rewards are tantalizing, but the risks? They're towering, too.
Read Also: 
<ul>
<li><a href="https://benzinga.com/news/earnings/24/11/42160175/us-stocks-likely-to-open-on-a-positive-note-as-trumps-treasury-secretary-pick-uplifts-investor-sentiment-expert-says-bull-market-is-alive-and-well">US Stocks Likely To Open On A Positive Note As Trump&#8217;s Treasury Secretary Pick Uplifts Investor Sentiment: Expert Says &#8216;Bull Market Is Alive And Well&#8217;</a></li>
</ul>
Image: Shutterstock

Movers

SMCI

SMCI Surges 65% In A Week, But Is Volatility The New Normal?

Macy's <a href="https://www.benzinga.com/24/11/42162655/macy-falls-as-preliminary-q3-highlights-mixed-performance-and-154-million-expense-concealment">delayed its Q3 earnings release</a>, revealing an internal investigation into an employee who allegedly hid hundreds of millions of dollars in expenses.
Shares of Macy&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) are trading lower on Monday, and there is a good chance that the downtrend will continue.
This is why it is our Stock of the Day.
A person who was responsible for small package delivery expense accounting made intentional &#8220;erroneous accounting accrual entries.&#8221; As much as $154 million may have been hidden. The activity occurred between Q4 2021 and the current third quarter.
Macy's said there was &#8220;no indication that the accounting error had any impact on the cash management activities or vendor payments.&#8221; It also said the employee is no longer with the company.
Read Also: <a href="https://www.benzinga.com/news/24/11/42093639/why-macys-stock-is-falling">Why Macy&#8217;s Stock Is Falling</a>
The stock was looking technically vulnerable prior to the news coming out. As you can see on the chart, it had run into resistance again around the $16.40 level. Stocks tend to sell off after they hit resistance. This is what happened with Macy's in mid-October and early November.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="557" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25101907/m-chart-1024x557.webp" alt="" class="wp-image-663574" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25101907/m-chart-1024x557.webp 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25101907/m-chart-300x163.webp 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25101907/m-chart-768x418.webp 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25101907/m-chart.webp 1501w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
When a stock trends higher, there aren't enough sellers to fill all the buy orders. As a result, buyers are forced to bid successively higher prices to attract sellers into the market, forcing the stock into an uptrend.
When resistance is reached, the uptrend ends. There are more than enough sellers to fill all of the buy orders. Buyers can acquire all of the shares they wish to without pushing the price any higher.
Sometimes, some investors and traders who create resistance with their sell orders become concerned. They know the buyers will go to whoever will sell at the lowest price.
They fear that other sellers may lower their asking prices, prompting them to do the same. This behavior often triggers a chain reaction, with more sellers reducing their prices in response.
It results in a snowball effect that can push the price lower.
This is what happened the last two times Macy's reached the $16.40 level, and it may be about to happen again.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/11/42154628/larry-page-google-co-founder-said-hed-leave-his-fortune-to-elon-musk-over-charity-because-of-his-plans-to-go-to-mars-to-back-up-humanity">Larry Page, Google Co-Founder, Said He&#8217;d Leave His Fortune To Elon Musk Over Charity Because Of His Plans &#8216;To Go To Mars To Back Up Humanity&#8217;</a></li>
</ul>
Photo: Shutterstock

Stock Of The Day: Macy's Hits Resistance Following Accounting Scandal

BCOV

Brightcove shares are trading higher after the company announced it entered into a definitive agreement to be acquired by Bending Spoons.

SmartKem shares are trading higher after the company announced it partnered with AUO to jointly develop a rollable, transparent microLED display.

JMP Securities analyst Jordan Bender maintains Caesars Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>) with a Market Outperform and lowers the price target from $59 to $57.

JMP Securities Maintains Market Outperform on Caesars Entertainment, Lowers Price Target to $57

QMCO

Quantum Corp Shares Resumed Trade

U.S. stocks were higher, with the Dow Jones index gaining more than 400 points on Monday.
Shares of BridgeBio Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) rose sharply during Monday's session after the company announced that the FDA approved Attruby to <a href="https://www.benzinga.com/24/11/42163927/fda-approves-bridgebio-pharmas-drug-for-rare-heart-disease-poised-to-challenge-pfizer-in-lucrative-yet-competitive-market">treat adults with ATTR-CM.</a>
On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization. Also, HC Wainwright maintained a Buy rating on the stock and raised its price target from $43 to $49.
BridgeBio Pharma shares jumped 22.3% to $28.64 on Monday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) shares jumped 69% to $2.9289 after the company completed a $100 million at-the-market equity offering, with plans to use the proceeds for working capital, capital expenditures, and advancements in superconducting quantum computing technology.</li>
<li>Scholar Rock Holding Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRRK#NASDAQ">SRRK</a>) gained 27.2% to $38.03. Scholar Rock Holding recently reported worse-than-expected third-quarter EPS results.</li>
<li>D-Wave Quantum Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NASDAQ">QBTS</a>) surged 26.3% to $3.6800 after AWS announced Quantum Embark program.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFH#NASDAQ">MFH</a>) gained 23.3% to $6.15.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) rose 19% to $7.26 after AWS announced Quantum Embark program.</li>
<li>Eastman Kodak Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) surged 17.4% to $6.18.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) rose 16.6% to $38.36.</li>
<li>Eve Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) gained 16.6% to $3.9062.</li>
<li>Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) shares climbed 15.5% to $35.49 after the company reported better-than-expected third-quarter EPS and sales and raised its 2024 guidance.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) surged 14.6% to $6.92.</li>
<li>Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) rose 13.5% to $28.77.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) gained 11.3% to $9.52.</li>
<li>Clarivate Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLVT#NYSE">CLVT</a>) rose 8.7% to $5.70.</li>
<li>Flagstar Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLG#NYSE">FLG</a>) gained 7.1% to $12.52.</li>
<li>Five Below, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) climbed 6.8% to $92.82. Five Below will release its financial results for the third quarter of fiscal 2024 after the closing bell on Wednesday, Dec. 4.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) climbed 6.3% to $43.74.</li>
<li>Jones Lang LaSalle Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) gained 6.1% to $279.28. Wolfe Research analyst Andrew Rosivach upgraded Jones Lang LaSalle from Peer Perform to Outperform and announced a $353 price target.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) rose 6% to $114.49 after Wedbush upgraded the stock from Neutral to Outperform and announced a $135 price target.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

ACHR

BBIO

BBWI

CLVT

ESTC

EVEX

FIVE

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IOVA

KODK

MRNA

QBTS

QUBT

RGTI

SRRK

BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday

Warning: SOPA is at high risk of performing badly

Society Pass regains compliance with Nasdaq minimum closing bid price rule

In a report released yesterday, Allen Klee from Maxim Group maintained a Hold rating on Society Pass (SOPA – Research Report). The company's shares...

Maxim Group Remains a Hold on Society Pass (SOPA)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Making millions through the stock market is only possible in a few ways. Investors need one of these three things: 



<ul><li>Massive sums of capital to begin with</li>



<li>Decades of time and more modest sums of capital</li>



<li>More modest sums of capital and a combination of risk and luck</li>
</ul>We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025. The standard caveat applies here, which says investors should only spend what they are willing to lose. 



Investing in sub-$2 stocks is very risky. Direct the majority of your capital toward more stable, conservative approaches. Direct much less capital to these riskier stocks that will require a combination of risk and luck.



All of the stocks discussed below cost less than $2 per share meaning $1,000 will get you at least 500 shares. Those 500 or more shares have the potential to appreciate in value above $10,000 by 2025.



<h2>Reliance Global (RELI)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/08/insurance-300x169.jpg" alt="Man in suit with hands over paper cutouts of family, car and home. Represents insurance."><div>Source: thodonal88 / Shutterstock.com</div></div>Reliance Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/reli-stock-quote/">RELI</a>) is a business group that acquires and manages retail insurance agencies in the United States. I chose to lead off the article with this stock specifically because it is not a pharma firm or another biotech stock. The purpose in doing so is not to say that <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks</a> are bad. Instead, it is to show there are plenty of 10X <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> outside of the biotech sector.



As I mentioned, there is a lot of risk in investing in shares of stocks trading at these levels. Investing in Reliance Global will be no different. The stock has lost roughly 95% of its value over the last 12 months. It currently trades for 25 cents per share. That should logically raise a lot of red flags for investors. However, there are reasons to believe that the company can rebound from here. 



Primarily, the company recently announced a definitive agreement to acquire Spetner Associates. The integration of Spetner Associates is expected to double Reliance Global&rsquo;s annual revenues to $28 million.&nbsp;



That news was <a href="https://www.globenewswire.com/news-release/2024/05/15/2882429/0/en/Reliance-Global-Group-Announces-Game-Changing-Acquisition-of-Spetner-Associates-Projected-to-Double-Company-s-Revenue.html">announced on May 15</a> and sent share prices drastically higher. The bet at this time is the integration of the new partner will again significantly increase revenues. Despite the obvious risk, that&rsquo;s the clear narrative behind investing in Reliance Global.



<h2>aTyr Pharma (LIFE)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/droplet-test-tube-biotech-1600-3-300x169.jpg" alt="Photo of test tubes and droplet with purple and reddish-orange sunset visual effect, representing biotech"><div>Source: shutterstock.com/Romix Image</div></div>aTyr Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/life-stock-quote/">LIFE</a>) is a biotech stock focused on the treatment of lung diseases that lead to fibrosis, or scarring of the lung tissue.



It appears to be among the better biotech stocks to bet on at this time. The company&rsquo;s lead candidate drug, Efzofitimod, has received FDA and EU orphan drug designation. That effectively fast tracks its development for the treatment of sarcoidosis and scleroderma.



The company also has a deal in place with Japan&rsquo;s Kyorin Pharmaceutical worth up to $175 million To develop and commercialize Efzofitimod in Japan. The company&rsquo;s pipeline of drugs extends beyond Efzofitimod with that drug being the clear catalyst overall.&nbsp;



LIFE shares currently trade for $1.76 and <a href="https://stockanalysis.com/stocks/life/forecast/">have a consensus target price above $25</a>.&nbsp;



The company continues to release <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-second-positive-dsmb-review-efzofitimod">positive news about its lead candidate drug</a>. That is not the only good news surrounding aTyr Pharma. The company also announced inducement grants that allowed <a href="https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-inducement-grants-under-nasdaq-listing-4">two employees to purchase 9,400 shares of stock at $1.86</a>. That suggests there is an immediate upside in LIFE stock at the moment.



<h2>BioLineRx (BLRX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/10/biotechnology1600-300x169.png" alt="Biotechnology stocks, biomedical stocks"><div>Source: aslysun / Shutterstock.com</div></div>BioLineRx (NASDAQ:<a href="https://investorplace.com/stock-quotes/blrx-stock-quote/">BLRX</a>) is a company attempting to commercialize therapeutics for the treatment of various cancers and rare diseases including sickle cell disease. The company&rsquo;s recent announcements around those projects deserve particular attention and make the stock attractive.



BioLineRx truly does look like a biotech stock that&rsquo;s about to move much higher. Interested investors should read this <a href="https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2024-financial-results-and-recent-corporate-and-portfolio-updates-302156149.html">recent portfolio update from May 28</a>. The company&rsquo;s FDA-approved multiple myeloma treatment, Aphexda, is growing steadily in its first full quarter of post-approval adoption.&nbsp;



The drug is quickly making its way into the network of transplant centers and is placed at 26% of all institutions in the U.S. currently. BioLineRx expects that number to rise to 35% by the end of the second quarter and could rise to 60% by the end of the year.



The biotech is currently running at a slight net loss of $0.7 million but benefits from continued progress in clinical trials relating to other diseases including sickle cell disease. In short, there seem to be multiple reasons to bet on BLRX stock at the moment.



<h2>Knightscope (KSCP)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2023/08/kscp1600-300x169.png" alt="Knightscope (KSCP) security robot patrols an outdoor parking lot"><div>Source: Michael Vi / Shutterstock.com</div></div>Knightscope (NASDAQ:<a href="https://investorplace.com/stock-quotes/kscp-stock-quote/">KSCP</a>) stock represents a company that builds fully autonomous security robots. Honestly, its products look a bit like something out of a dystopian future movie from the &rsquo;90s. Despite that, Knightscope&rsquo;s progress makes it very interesting for investors.



The company hasn&rsquo;t released highly detailed financial statements but the most recent indication that we have is from March. That report <a href="https://ir.knightscope.com/news-releases/news-release-details/knightscope-2023-estimated-revenues-increase-128-128-million">showed revenues increased by 128% to $12.8 million </a>during 2023. The report also includes some images of the company&rsquo;s AI-enabled security robots that are a bit cyberpunk and Robocop.&nbsp;



The company released another report days later updating the company&rsquo;s financial position. It showed that the company&rsquo;s net loss narrowed from $25.6 million to $22.1 million in 2023. It also noted the company has 10,000 machines in its network across the United States and the company plans to reduce its payroll expense by 30% this year.



The company has since <a href="https://ir.knightscope.com/news-and-events/news">won multiple contracts and deployed multiple tranches </a>of robots.&nbsp;



<h2>Adial Pharmaceuticals (ADIL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Adial Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/adil-stock-quote/">ADIL</a>) is a company working to address addiction disorders that are quite rampant across society. The reason to believe in the stock lies in its lead candidate drug, AD04. That drug is intended to treat alcohol use disorder, opioid use disorder and a host of potential other drug dependencies.&nbsp;



The company has identified a range of genetic phenotypes that respond to AD04. Adial Pharmaceuticals estimates that represents a $40 billion opportunity in the U.S. alone.



The company also secured patent rights protecting the ability of that drug to target specific gene sequences relating to various drug dependency disorders.&nbsp;



The company is clearly very interesting for its positioning relative to various substance dependencies and their overall socioeconomic burden. However, potential investors should also be aware the company&rsquo;s&nbsp;current liquidity only covers the company through the first quarter of 2025. Regardless, substance disorder pharmaceutical firms are a rapidly growing sub-sector within the industry and Adial Pharmaceuticals could certainly emerge as a winner.&nbsp;



<h2>Society Pass (SOPA)&nbsp;</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/07/fintech_1600-300x169.jpg" alt='undervalued fintech stocks A concept image of a hand reaching toward the word "Fintech," which is surrounded by icons representing money and growth. Fintech Stock Bargains, fintech stock'><div>Source: Wright Studio / Shutterstock.com</div></div>Investors interested in the outsized growth prospects in Southeast Asia should take a look at Society Pass (NASDAQ:<a href="https://investorplace.com/stock-quotes/sopa-stock-quote/">SOPA</a>). The company continues to build an ecosystem encompassing e-commerce and fintech worth understanding at least.



The <a href="https://www.globenewswire.com/news-release/2023/12/07/2792494/0/en/Society-Pass-Inc-Nasdaq-SOPA-Ascendiant-Capital-Issues-3Q-2023-Equity-Research-Update-3Q-Results-Show-Solid-Revenue-Growth-and-Maintains-Positive-Outlook-on-Growth-Prospects.html">most recent earnings report</a> from the third quarter of 2023 shows that revenues grew by 11%. Clearly, that&rsquo;s not the sort of outsized growth many seek from emerging market opportunities. Nevertheless, there are things to like about Society Pass. What I like is that the company has zero debt and $8 million in cash.&nbsp;&nbsp;



Despite a net loss of $3.9 million in the period, the company managed to report a modest gross profit of $600,000. The company also has a $40 million line of credit should that ultimately be necessary. That line of credit is an indication institutional investors see the overall opportunity represented by Society Pass. Much like Adial Pharmaceutical, Society Pass is interesting for operating within a high-growth sub-sector that may not get as much attention as it deserves.



<h2>Enviva (EVA)</h2>



<div><img width="300" height="200" src="https://investorplace.com/wp-content/uploads/2022/01/carbon-dioxide-1600-300x200.png" alt="Environmental pollution, environmental problem, smoke from the chimney of an industrial plant or thermal power plant against a cloudy sky"><div>Source: AYDO8 / Shutterstock.com</div></div>Investing in Enviva (NYSE:<a href="https://investorplace.com/stock-quotes/eva-stock-quote/">EVA</a>) stock will appeal to green investors&nbsp;and industrial investors looking for turnaround opportunities. The company produces sustainable wood pellets intended to provide a low-carbon alternative to fossil fuels.



While the company has some interesting, promising catalysts, it is going through a transition as it attempts to affect a turnaround. The most recent earnings reports &mdash; from November 2023 &mdash; gets into those details.



Most of the report focused on the appointment of the company&rsquo;s previous CFO to an interim CEO position. He is essentially tasked with turning around deepening losses and righting the course for Enviva. The <a href="https://ir.envivabiomass.com/news/news-details/2023/Enviva-Reports-3Q-2023-Results/default.aspx">fundamentals tell the story of a company in trouble</a>. Revenues fell by a modest 1.3% in that report while net losses more than quadrupled to $85.2 million.&nbsp;



The company has <a href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0001592057/5aee415d-4604-4366-a34d-18c777395a61.pdf">not filed any subsequent financial reports</a> since November. It&rsquo;s clearly at risk of bankruptcy and restructuring. My sense is that the company&rsquo;s shares will trend downward but they certainly do <a href="https://stockanalysis.com/stocks/eva/forecast/">have the potential to 10X</a> nonetheless.&nbsp;



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions,&nbsp;InvestorPlace does not publish commentary about companies that have a market cap of&nbsp;less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because&nbsp;these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market&nbsp;manipulators. If we ever do publish commentary on a low-volume stock that may be&nbsp;affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this&nbsp;fact and warn readers of the risks.



Read More:&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/06/millionaire-makers-7-stocks-you-can-buy-for-2-that-can-10x-by-2025/">Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025

The latest announcement is out from Society Pass (SOPA). Society Pass Incorporated witnessed a shift in its leadership as board members John Mackay...

Society Pass Leadership Overhaul and Board Expansion

Society Pass (SOPA) just unveiled an update. Jeremy Miller and Tan Bien Kiat have stepped down from their roles as directors of Society Pass Incorp...

Society Pass Announces Amicable Board Reshuffle

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic as we dive into all of the biggest news traders need to know about on Monday morning!



Moving stocks this morning are an acquisition deal, a strategic alliance, earnings data and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Tellurian (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tell-stock-quote/">TELL</a>) stock is rocketing more than 66% <a href="https://finance.yahoo.com/news/tellurian-acquired-woodside-approximately-900-222900949.html">due to a $900 million acquisition deal</a>.</li>



<li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) shares are soaring over 60% after Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>) <a href="https://investorplace.com/2024/07/serv-stock-soars-as-nvidia-reveals-big-bet-on-serve-robotics/">revealed a stake in the company</a>.</li>



<li>Castellum (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ctm-stock-quote/">CTM</a>) stock is surging more than 56% after <a href="https://www.nasdaq.com/press-release/castellum-inc-announces-strategic-alliance-k2-2024-07-22">announcing a strategic alliance</a>.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) shares are rising over 40% alongside heavy pre-market trading.</li>



<li>Richtech Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rr-stock-quote/">RR</a>) stock is increasing more than 27% after <a href="https://www.nasdaq.com/press-release/richtech-robotics-celebrates-completion-installation-adam-ghost-kitchens-inside">adding ADAM to certain ghost kitchens</a>.</li>



<li>CISO Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/ciso-stock-quote/">CISO</a>) shares are gaining over 24% after announcing <a href="https://www.nasdaq.com/press-release/ciso-global-announces-solution-mitigate-impact-crowdstrike-security-event-2024-07-19">a way to mitigate damage</a> from the CrowdStrike (NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>) issues last week.</li>



<li>Tellurian Inc. 8.25% Senior Notes due 2028 (NYSEMKT:<a href="https://investorplace.com/stock-quotes/telz-stock-quote/">TELZ</a>) are heading more than 21% higher this morning.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) stock is climbing over 18% without any clear news this morning.</li>



<li>Society Pass (NASDAQ:<a href="https://investorplace.com/stock-quotes/sopa-stock-quote/">SOPA</a>) shares are jumping more than 17% on Monday morning.</li>



<li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is up over 16% without any clear news today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) stock is plummeting more than 24% after a major rally on Friday.</li>



<li>Sentage (NASDAQ:<a href="https://investorplace.com/stock-quotes/sntg-stock-quote/">SNTG</a>) shares are diving over 14% on Monday morning.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) stock is tumbling close to 14% this morning.</li>



<li>Novo Integrated Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvos-stock-quote/">NVOS</a>) shares are taking a nearly 14% beating after <a href="https://investorplace.com/earning-results/2024/07/nvos-stock-earnings-novo-integrated-sciences-for-q3-of-2024/">jumping Friday on earnings</a>.</li>



<li>Safe &amp; Green Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/">SGD</a>) stock is sliding over 13% on Monday morning.</li>



<li>Ryanair (NASDAQ:<a href="https://investorplace.com/stock-quotes/ryaay-stock-quote/">RYAAY</a>) shares are falling more than 13% alongside <a href="https://www.cnbc.com/2024/07/22/ryanair-q1-2024-results-shares-fall-on-lower-fares-fall-in-quarterly-profit.html">falling quarterly profit</a>.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) stock is dropping over 11% on Monday.</li>



<li>Stronghold Digital Mining (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdig-stock-quote/">SDIG</a>) shares are decreasing more than 11% this morning.</li>



<li>60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) stock is slipping over 10% on Monday morning.</li>



<li>PS International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares close out our pre-market stock movers down almost 10% on Monday.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-july-22nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Society Pass (NASDAQ:<a href="https://investorplace.com/stock-quotes/sopa-stock-quote/">SOPA</a>) just reported results for the second quarter of 2024.<ul><li>Society Pass reported earnings per share of -73 cents. This was above the analyst estimate for EPS of -83 cents.</li><li>The company reported revenue of $1.71 million.</li><li>This was 23.96% worse than the analyst estimate for revenue of $2.25 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/sopa-stock-earnings-society-pass-for-q2-of-2024/">SOPA Stock Earnings: Society Pass Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SOPA Stock Earnings: Society Pass Beats EPS, Misses Revenue for Q2 2024

Maxim Group analyst Allen Klee maintained a Hold rating on Society Pass (SOPA – Research Report) yesterday. The company's shares closed yesterday a...

Maxim Group Sticks to Its Hold Rating for Society Pass (SOPA)

ADIL

BLRX

CISO

CRWD

LIFE

NCPL

NUZE

NVOS

PRTG

PSIG

RELI

RYAAY

SDIG

SERV

SNOA

SNTG

SOPA

SXTP

TELL

TELZ

XCUR

Press Releases

Society Pass Inc. (Nasdaq: SOPA)/Thoughtful Media Group Inc (TMG): Greenridge Global Initiates Equity Research Coverage on TMG; TMG To Capture Significant Advertising Market Share In Southeast Asia

Society Pass Inc. (Nasdaq: SOPA): Litchfield Hills Initiates Equity Research Coverage; SOPA Growing Rapidly and Nearing Positive EBITDA Inflection

Society Pass Inc. (Nasdaq: SOPA) 1Q 2024 Shareholder Update and Analyst Recommendations

Small Cap

Opinion

Thinking about buying stock in Certara, Stronghold Digital Mining, Society Pass, AgriFORCE Growing Systems, or Luxurban Hotels?

Financing

Society Pass Inc. Issues First Advance Notice to Strattners Bank, to Continue its Growth Plans

Society Pass Incorporated Announces 1-for-15 Reverse Split

Society Pass Set to Unlock and Monetize Current and Future Subsidiary Spin-Off Opportunities Through Strong and Flexible Financing

Society Pass Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Ascendiant Capital publishes a company update on Society Pass (NASDAQ: SOPA), expecting strong growth over the next year

IPOs

Society Pass Inc. Bolstering Subsidiaries Ahead of IPOs to Drive Growth and Customer Engagement

Comments

Society Pass

Noticias

Últimas noticias sobre Society Pass (NASDAQ:SOPA) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL